{"title":"颅内动脉狭窄患者血管内治疗后脑梗死的内皮糖萼","authors":"Fangfang Zhao, Tao Wang, Jichang Luo, Haoyuan Gao, Yangmin Zheng, Rongliang Wang, Junfen Fan, Haiping Zhao, Ziping Han, Yumin Luo, Liqun Jiao","doi":"10.1111/cns.70545","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>To examine whether plasma glycocalyx levels in patients with severe intracranial arterial stenosis (ICAS) are associated with the prediction of new cerebral infarctions following endovascular treatment.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>105 patients with ICAS who underwent endovascular treatment were enrolled from September 2020 to June 2021. Plasma glycocalyx components were detected. The condition of the cerebral artery was obtained by high-resolution nuclear magnetic resonance, and risk factors for new cerebral infarction postendovascular treatment in patients with ICAS were analyzed using both univariate and multivariate analyses. The results were presented in a nomogram risk model and evaluated.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The plasma glycocalyx in patients with ICAS exhibited significant differences compared to healthy individuals (<i>p</i> < 0.05). Multivariate analysis revealed eccentricity (OR = 3.599, 95% CI: 1.168–12.478, <i>p</i> = 0.032) and hyaluronic acid (OR = 5.542, 95% CI: 1.545–23.573, <i>p</i> = 0.013) as risk factors (<i>p</i> < 0.05). The risk model encompassing eccentricity, Remodeling index, blood glucose, hyaluronic acid (HA), and age was presented as a Nomogram, with a C-index of 0.810 (95% CI, 0.729–0.890). To further analyze the risk factors affecting HA plasma concentration, the multivariate analysis showed that fibrinogen and hemoglobin A1c (HbA1C) significantly affected changes in HA.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>We found that HA is a critical factor in predicting adverse events of cerebral infarction after endovascular treatment in patients with ICAS. Additionally, HbA1C and fibrinogen were identified as factors influencing HA changes.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>ClinicalTrials.gov Identifier: NCT01994161</p>\n </section>\n </div>","PeriodicalId":154,"journal":{"name":"CNS Neuroscience & Therapeutics","volume":"31 8","pages":""},"PeriodicalIF":5.0000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cns.70545","citationCount":"0","resultStr":"{\"title\":\"Endothelial Glycocalyx in Cerebral Infarction After Endovascular Treatment in Patients With Intracranial Artery Stenosis\",\"authors\":\"Fangfang Zhao, Tao Wang, Jichang Luo, Haoyuan Gao, Yangmin Zheng, Rongliang Wang, Junfen Fan, Haiping Zhao, Ziping Han, Yumin Luo, Liqun Jiao\",\"doi\":\"10.1111/cns.70545\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>To examine whether plasma glycocalyx levels in patients with severe intracranial arterial stenosis (ICAS) are associated with the prediction of new cerebral infarctions following endovascular treatment.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>105 patients with ICAS who underwent endovascular treatment were enrolled from September 2020 to June 2021. Plasma glycocalyx components were detected. The condition of the cerebral artery was obtained by high-resolution nuclear magnetic resonance, and risk factors for new cerebral infarction postendovascular treatment in patients with ICAS were analyzed using both univariate and multivariate analyses. The results were presented in a nomogram risk model and evaluated.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The plasma glycocalyx in patients with ICAS exhibited significant differences compared to healthy individuals (<i>p</i> < 0.05). Multivariate analysis revealed eccentricity (OR = 3.599, 95% CI: 1.168–12.478, <i>p</i> = 0.032) and hyaluronic acid (OR = 5.542, 95% CI: 1.545–23.573, <i>p</i> = 0.013) as risk factors (<i>p</i> < 0.05). The risk model encompassing eccentricity, Remodeling index, blood glucose, hyaluronic acid (HA), and age was presented as a Nomogram, with a C-index of 0.810 (95% CI, 0.729–0.890). To further analyze the risk factors affecting HA plasma concentration, the multivariate analysis showed that fibrinogen and hemoglobin A1c (HbA1C) significantly affected changes in HA.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>We found that HA is a critical factor in predicting adverse events of cerebral infarction after endovascular treatment in patients with ICAS. Additionally, HbA1C and fibrinogen were identified as factors influencing HA changes.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Trial Registration</h3>\\n \\n <p>ClinicalTrials.gov Identifier: NCT01994161</p>\\n </section>\\n </div>\",\"PeriodicalId\":154,\"journal\":{\"name\":\"CNS Neuroscience & Therapeutics\",\"volume\":\"31 8\",\"pages\":\"\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2025-08-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cns.70545\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CNS Neuroscience & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/cns.70545\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Neuroscience & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cns.70545","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Endothelial Glycocalyx in Cerebral Infarction After Endovascular Treatment in Patients With Intracranial Artery Stenosis
Objective
To examine whether plasma glycocalyx levels in patients with severe intracranial arterial stenosis (ICAS) are associated with the prediction of new cerebral infarctions following endovascular treatment.
Methods
105 patients with ICAS who underwent endovascular treatment were enrolled from September 2020 to June 2021. Plasma glycocalyx components were detected. The condition of the cerebral artery was obtained by high-resolution nuclear magnetic resonance, and risk factors for new cerebral infarction postendovascular treatment in patients with ICAS were analyzed using both univariate and multivariate analyses. The results were presented in a nomogram risk model and evaluated.
Results
The plasma glycocalyx in patients with ICAS exhibited significant differences compared to healthy individuals (p < 0.05). Multivariate analysis revealed eccentricity (OR = 3.599, 95% CI: 1.168–12.478, p = 0.032) and hyaluronic acid (OR = 5.542, 95% CI: 1.545–23.573, p = 0.013) as risk factors (p < 0.05). The risk model encompassing eccentricity, Remodeling index, blood glucose, hyaluronic acid (HA), and age was presented as a Nomogram, with a C-index of 0.810 (95% CI, 0.729–0.890). To further analyze the risk factors affecting HA plasma concentration, the multivariate analysis showed that fibrinogen and hemoglobin A1c (HbA1C) significantly affected changes in HA.
Conclusion
We found that HA is a critical factor in predicting adverse events of cerebral infarction after endovascular treatment in patients with ICAS. Additionally, HbA1C and fibrinogen were identified as factors influencing HA changes.
期刊介绍：
CNS Neuroscience & Therapeutics provides a medium for rapid publication of original clinical, experimental, and translational research papers, timely reviews and reports of novel findings of therapeutic relevance to the central nervous system, as well as papers related to clinical pharmacology, drug development and novel methodologies for drug evaluation. The journal focuses on neurological and psychiatric diseases such as stroke, Parkinson’s disease, Alzheimer’s disease, depression, schizophrenia, epilepsy, and drug abuse.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
